130 related articles for article (PubMed ID: 22475424)
1. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.
Srivastava SC
Semin Nucl Med; 2012 May; 42(3):151-63. PubMed ID: 22475424
[TBL] [Abstract][Full Text] [Related]
2. Options to meet the future global demand of radionuclides for radionuclide therapy.
Das T; Pillai MR
Nucl Med Biol; 2013 Jan; 40(1):23-32. PubMed ID: 23116551
[TBL] [Abstract][Full Text] [Related]
3. The necessity of nuclear reactors for targeted radionuclide therapies.
Krijger GC; Ponsard B; Harfensteller M; Wolterbeek HT; Nijsen JW
Trends Biotechnol; 2013 Jul; 31(7):390-6. PubMed ID: 23731577
[TBL] [Abstract][Full Text] [Related]
4. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
[TBL] [Abstract][Full Text] [Related]
5. A vector Wiener filter for dual-radionuclide imaging.
Links JM; Prince JL; Gupta SN
IEEE Trans Med Imaging; 1996; 15(5):700-9. PubMed ID: 18215951
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
Maecke HR; Reubi JC
J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
8. Radiopharmaceutical chemistry for positron emission tomography.
Li Z; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1031-51. PubMed ID: 20854860
[TBL] [Abstract][Full Text] [Related]
9. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
Zanzonico P; Dauer L; St Germain J
Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
[TBL] [Abstract][Full Text] [Related]
10. Advances in SPECT imaging with respect to radionuclide therapy.
D'Asseler Y
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):343-7. PubMed ID: 19521314
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
12. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions.
Lanconelli N; Pacilio M; Lo Meo S; Botta F; Di Dia A; Aroche AT; Pérez MA; Cremonesi M
Phys Med Biol; 2012 Jan; 57(2):517-33. PubMed ID: 22217735
[TBL] [Abstract][Full Text] [Related]
13. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.
Tolmachev V; Carlsson J; Lundqvist H
Acta Oncol; 2004; 43(3):264-75. PubMed ID: 15244250
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide production and yields at Washington University School of Medicine.
Tang L
Q J Nucl Med Mol Imaging; 2008 Jun; 52(2):121-33. PubMed ID: 18043542
[TBL] [Abstract][Full Text] [Related]
15. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy.
Hamacher KA; Den RB; Den EI; Sgouros G
J Nucl Med; 2001 Aug; 42(8):1216-21. PubMed ID: 11483682
[TBL] [Abstract][Full Text] [Related]
16. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
[TBL] [Abstract][Full Text] [Related]
17. Patient-specific internal radionuclide dosimetry.
Tsougos I; Loudos G; Georgoulias P; Theodorou K; Kappas C
Nucl Med Commun; 2010 Feb; 31(2):97-106. PubMed ID: 20032767
[TBL] [Abstract][Full Text] [Related]
18. [Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use].
Lundqvist H; Carlsson J; Gedda L; Tolmachev V; Garske U; Kairemo K
Lakartidningen; 2004 Mar; 101(11):1000-2, 1005-6. PubMed ID: 15055121
[TBL] [Abstract][Full Text] [Related]
19. Targeting peptides and positron emission tomography.
Lundqvist H; Tolmachev V
Biopolymers; 2002; 66(6):381-92. PubMed ID: 12658725
[TBL] [Abstract][Full Text] [Related]
20. Is there life after technetium: what is the potential for developing new broad-based radionuclides?
Srivastava SC
Semin Nucl Med; 1996 Apr; 26(2):119-31. PubMed ID: 8723506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
